<H1>Chapter DOI: 10.1007/s00105-015-3644-7<br/>Cited-By Count: 1</H1><table border="1" width="30%"><tr><td>Total References</td><td>49</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>47</td></tr><tr><td>BibStructured Count</td><td width="10%">48</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>48</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>0</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>0</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>-1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Liu Z, Davidson A (2012) Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med 18:871&#8211;882</td><td><a href=http://dx.doi.org/10.1038/nm.2752>10.1038/nm.2752</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Werth VP (2005) Clinical manifestations of cutaneous lupus erythematosus. Autoimmun Rev 4:296&#8211;302</td><td><a href=http://dx.doi.org/10.1016/j.autrev.2005.01.003>10.1016/j.autrev.2005.01.003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Kuhn A, Sticherling M, Bonsmann G (2007) Clinical manifestations of cutaneous lupus erythematosus. J Dtsch Dermatol Ges 5:1124&#8211;1137</td><td><a href=http://dx.doi.org/10.1111/j.1610-0387.2007.06554.x>10.1111/j.1610-0387.2007.06554.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Yell JA, Mbuagbaw J, Burge SM (1996) Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 135:355&#8211;362</td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.1996.tb01495.x>10.1111/j.1365-2133.1996.tb01495.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Albrecht J, Berlin JA, Braverman IM et al (2004) Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. Lupus 13:839&#8211;849</td><td><a href=http://dx.doi.org/10.1191/0961203304lu2020oa>10.1191/0961203304lu2020oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Petri M, Orbai AM, Alarcon GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677&#8211;2686</td><td><a href=http://dx.doi.org/10.1002/art.34473>10.1002/art.34473</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Rhodes B, Vyse TJ (2008) The genetics of SLE: an update in the light of genome-wide association studies. Rheumatology (Oxford) 47:1603&#8211;1611</td><td><a href=http://dx.doi.org/10.1093/rheumatology/ken247>10.1093/rheumatology/ken247</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Gunther C (2015) [Genetics of lupus erythematosus]. Hautarzt 66:121&#8211;130</td><td><a href=http://dx.doi.org/10.1007/s00105-014-3570-0>10.1007/s00105-014-3570-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Cutolo M, Sulli A, Capellino S et al (2004) Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. Lupus 13:635&#8211;638</td><td><a href=http://dx.doi.org/10.1191/0961203304lu1094oa>10.1191/0961203304lu1094oa</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Cervera R, Khamashta MA, Hughes GR (2009) The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus 18:869&#8211;874</td><td><a href=http://dx.doi.org/10.1177/0961203309106831>10.1177/0961203309106831</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Foering K, Chang AY, Piette EW et al (2013) Characterization of clinical photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol 69:205&#8211;213</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2013.03.015>10.1016/j.jaad.2013.03.015</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Kuhn A, Sigges J, Biazar C et al (2014) Influence of smoking on disease severity and antimalarial therapy in cutaneous lupus erythematosus: analysis of 1002 patients from the EUSCLE database. Br J Dermatol 171:571&#8211;579</td><td><a href=http://dx.doi.org/10.1111/bjd.13006>10.1111/bjd.13006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Al-Mayouf SM, Sunker A, Abdwani R et al (2011) Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet 43:1186&#8211;1188</td><td><a href=http://dx.doi.org/10.1038/ng.975>10.1038/ng.975</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Yasutomo K, Horiuchi T, Kagami S et al (2001) Mutation of DNASE1 in people with systemic lupus erythematosus. Nat Genet 28:313&#8211;314</td><td><a href=http://dx.doi.org/10.1038/91070>10.1038/91070</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Toberer F, Sykora J, Gottel D et al (2013) Apoptotic signal molecules in skin biopsies of cutaneous lupus erythematosus: analysis using tissue microarray. Exp Dermatol 22:656&#8211;659</td><td><a href=http://dx.doi.org/10.1111/exd.12216>10.1111/exd.12216</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Kuhn A, Herrmann M, Kleber S et al (2006) Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum 54:939&#8211;950</td><td><a href=http://dx.doi.org/10.1002/art.21658>10.1002/art.21658</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Casciola-Rosen LA, Anhalt G, Rosen A (1994) Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317&#8211;1330</td><td><a href=http://dx.doi.org/10.1084/jem.179.4.1317>10.1084/jem.179.4.1317</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Bernard JJ, Cowing-Zitron C, Nakatsuji T et al (2012) Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat Med 18:1286&#8211;1290</td><td><a href=http://dx.doi.org/10.1038/nm.2861>10.1038/nm.2861</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Hansel A, Gunther C, Baran W et al (2013) Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus. J Autoimmun 40:1&#8211;8</td><td><a href=http://dx.doi.org/10.1016/j.jaut.2012.07.005>10.1016/j.jaut.2012.07.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Ganguly D, Chamilos G, Lande R et al (2009) Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 206:1983&#8211;1994</td><td><a href=http://dx.doi.org/10.1084/jem.20090480>10.1084/jem.20090480</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibArticle</td><td>Lande R, Gregorio J, Facchinetti V et al (2007) Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449:564&#8211;569</td><td><a href=http://dx.doi.org/10.1038/nature06116>10.1038/nature06116</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Hornung V (2014) SnapShot: nucleic acid immune sensors, part 2. Immunity 41:1066</td><td><a href=http://dx.doi.org/10.1016/j.immuni.2014.10.006>10.1016/j.immuni.2014.10.006</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Gehrke N, Mertens C, Zillinger T et al (2013) Oxidative damage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing. Immunity 39:482&#8211;495</td><td><a href=http://dx.doi.org/10.1016/j.immuni.2013.08.004>10.1016/j.immuni.2013.08.004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Ablasser A, Hemmerling I, Schmid-Burgk JL et al (2014) TREX1 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. J Immunol 192:5993&#8211;5997</td><td><a href=http://dx.doi.org/10.4049/jimmunol.1400737>10.4049/jimmunol.1400737</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Yang YG, Lindahl T, Barnes DE (2007) Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell 131:873&#8211;886</td><td><a href=http://dx.doi.org/10.1016/j.cell.2007.10.017>10.1016/j.cell.2007.10.017</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Stetson DB, Ko JS, Heidmann T et al (2008) Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134:587&#8211;598</td><td><a href=http://dx.doi.org/10.1016/j.cell.2008.06.032>10.1016/j.cell.2008.06.032</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Lee-Kirsch MA, Gong M, Chowdhury D et al (2007) Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet 39:1065&#8211;1067</td><td><a href=http://dx.doi.org/10.1038/ng2091>10.1038/ng2091</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Lee-Kirsch MA, Chowdhury D, Harvey S et al (2007) A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 85:531&#8211;537</td><td><a href=http://dx.doi.org/10.1007/s00109-007-0199-9>10.1007/s00109-007-0199-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR29</td><td>BibArticle</td><td>Gunther C, Kind B, Reijns MA et al (2015) Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest 125:413&#8211;424</td><td><a href=http://dx.doi.org/10.1172/JCI78001>10.1172/JCI78001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Moser KL, Kelly JA, Lessard CJ et al (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10:373&#8211;379</td><td><a href=http://dx.doi.org/10.1038/gene.2009.39>10.1038/gene.2009.39</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Celhar T, Fairhurst AM (2014) Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. Front Pharmacol 5:265</td><td><a href=http://dx.doi.org/10.3389/fphar.2014.00265>10.3389/fphar.2014.00265</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Liu Y, Jesus AA, Marrero B et al (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371:507&#8211;518</td><td><a href=http://dx.doi.org/10.1056/NEJMoa1312625>10.1056/NEJMoa1312625</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Wenzel J, Worenkamper E, Freutel S et al (2005) Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 205:435&#8211;442</td><td><a href=http://dx.doi.org/10.1002/path.1721>10.1002/path.1721</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Meller S, Winterberg F, Gilliet M et al (2005) Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52:1504&#8211;1516</td><td><a href=http://dx.doi.org/10.1002/art.21034>10.1002/art.21034</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Obermoser G, Pascual V (2010) The interferon-alpha signature of systemic lupus erythematosus. Lupus 19:1012&#8211;1019</td><td><a href=http://dx.doi.org/10.1177/0961203310371161>10.1177/0961203310371161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Loser K, Vogl T, Voskort M et al (2010) The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 16:713&#8211;717</td><td><a href=http://dx.doi.org/10.1038/nm.2150>10.1038/nm.2150</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ramos</span> <span style='background:#DDDDDD'>PS</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Shaftman</span> <span style='background:#DDDDDD'>SR</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Ward</span> <span style='background:#DDDDDD'>RC</span></span> et al</aug> (<span style='background:#66FF66'>2014</span>) <span style='background:#CCCCFF'>Genes associated with SLE are targets of recent positive selection</span>. <span style='background:#CCFF99'>Autoimmune Dis</span> <span style='background:#FFCC66'>2014</span>:<span style='background:#D279FF'>203435</span></td><td><a href=http://dx.doi.org/10.1155/2014/203435>10.1155/2014/203435</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, Year, VolumeID, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Kuznik A, Bencina M, Svajger U et al (2011) Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 186:4794&#8211;4804</td><td><a href=http://dx.doi.org/10.4049/jimmunol.1000702>10.4049/jimmunol.1000702</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Sigges J, Biazar C, Landmann A et al (2013) Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) core set questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 12:694&#8211;702</td><td><a href=http://dx.doi.org/10.1016/j.autrev.2012.10.005>10.1016/j.autrev.2012.10.005</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Merrill JT, Ginzler EM, Wallace DJ et al (2012) Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 64:3364&#8211;3373</td><td><a href=http://dx.doi.org/10.1002/art.34564>10.1002/art.34564</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Husein-ElAhmed H, Callejas-Rubio JL, Rios-Fernandez R et al (2014) Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody. Indian J Dermatol Venereol Leprol 80:477&#8211;478</td><td><a href=http://dx.doi.org/10.4103/0378-6323.140335>10.4103/0378-6323.140335</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Hofmann SC, Leandro MJ, Morris SD et al (2013) Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus&#8211;report of 17 cases and review of the literature. Lupus 22:932&#8211;939</td><td><a href=http://dx.doi.org/10.1177/0961203313497115>10.1177/0961203313497115</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Gunther C, Aringer M, Lochno M et al (2012) TNF-alpha blockade with infliximab in a patient with lupus erythematosus profundus. Acta Derm Venereol 92:401&#8211;403</td><td><a href=http://dx.doi.org/10.2340/00015555-1262>10.2340/00015555-1262</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR44</td><td>BibArticle</td><td>Napolitano M, Giampetruzzi AR, Didona D et al (2013) Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. J Am Acad Dermatol 69:e303&#8211;e305</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2013.07.036>10.1016/j.jaad.2013.07.036</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Okon L, Rosenbach M, Krathen M et al (2014) Lenalidomide in treatment-refractory cutaneous lupus erythematosus: efficacy and safety in a 52-week trial. J Am Acad Dermatol 70:583&#8211;584</td><td><a href=http://dx.doi.org/10.1016/j.jaad.2013.11.007>10.1016/j.jaad.2013.11.007</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J et al (2012) Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol 166:616&#8211;623</td><td><a href=http://dx.doi.org/10.1111/j.1365-2133.2011.10693.x>10.1111/j.1365-2133.2011.10693.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46&#8211;50</td><td><a href=http://dx.doi.org/10.1080/09546630310018789>10.1080/09546630310018789</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Wang B, Higgs BW, Chang L et al (2013) Pharmacogenomics and translational simulations to bridge indications for an anti-interferon-alpha receptor antibody. Clin Pharmacol Ther 93:483&#8211;492</td><td><a href=http://dx.doi.org/10.1038/clpt.2013.35>10.1038/clpt.2013.35</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Petri M, Wallace DJ, Spindler A et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65:1011&#8211;1021</td><td><a href=http://dx.doi.org/10.1002/art.37824>10.1002/art.37824</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>